CoronaryAtlas logo
CoronaryAtlas
Complement C5b-9 (MAC)
Pathway / Plaque inflammation

Complement C5b-9 (MAC)

complex

C5b-9 amplifies endothelial injury and inflammatory cell recruitment through complement-driven lysis and activation.

Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleComplement membrane-attack complex; direct inflammation marker elevated in AMI.
Also acts inEndothelial activation/erosion
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
—
C — non-Type-I
67
A — assay feasibility
58
E — evidence strength
8
T1DI (composite)
1
Specificity differential (R−C)-51.7
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmian/a
2hypoxemia / respiratory failuren/a
2hypertensive emergencyn/a
2high-demand / peri-operative stressn/a
3sudden cardiac deathn/a
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedn/a
Coverage: 1/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 2 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Plasma (citrate for coagulation complexes)
Collection tube
Sodium citrate 3.2% (light blue-top) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich ELISA against neo-complex epitope
Reagent / substrate
Antibody pair recognizing the assembled complex
Platform
ELISA plate
Turnaround · availability
Research / send-out · Research/specialized

Literature evidence(2)